De-Mont Research Laboratories (Pvt.) Ltd.
Private pharmaceutical manufacturer · Sheikhupura · Pakistan
Punjab-based pharmaceutical and healthcare manufacturer within the McOlson Group, focused on medicines and related healthcare products.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- DeMont Research Laboratories (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 20-KM Lahore-Sharaqpur Road, Sheikhupura, Pakistan
- Website
- demont.pk ↗
- Phone
- +92 42 35171711; +92 42 35160633
- info@demont.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Acovir AcyclovirSource observed | — | — | Dry suspension | 60ml | 084093Official source ↗ | No indexed price | — | — |
| ACTILOP : | Losartan | 50 mg | Tablet | 20's | 094680 | PKR 370.03 | PKR 18.50/tablet | 11% below median |
| ACTILOP- H 50 | Losartan + Hydrochlorothiazide | 50 mg + 12.5 mg | Tablet | 20's | 094681 | PKR 555.04 | PKR 27.75/tablet | 10% below median |
| Amlomont | Amlodipine | 5 mg | Tablet | 20's | 119050 | PKR 114.23 | PKR 5.71/tablet | 47% below median |
| Amlomont | Amlodipine | 10 mg | Tablet | 20's | 119053 | PKR 184.03 | PKR 9.20/tablet | 48% below median |
| Angi-C 10 | Amlodipine + Valsartan | 10 mg + 160 mg | Tablet | 14's | 094684 | PKR 653.17 | PKR 46.66/tablet | 7% below median |
| Angi-C 5 | Amlodipine + Valsartan | 5 mg + 160 mg | Tablet | 14's | 094685 | PKR 524.00 | PKR 37.43/tablet | 18% below median |
| Angi-C 5 | Amlodipine + Valsartan | 5 mg + 80 mg | Tablet | 14's | 094686 | PKR 389.33 | PKR 27.81/tablet | 13% below median |
| Aroma | Azithromycin | 250 mg | Tablet | 6's | 099911 | PKR 263.96 | PKR 43.99/tablet | 7% below median |
| Aroma | Azithromycin | 250 mg | Tablet | 10's | 099911 | PKR 492.02 | PKR 49.20/tablet | Near median |
| Aroma | Azithromycin | 500 mg | Tablet | 6's | 099912 | PKR 483.92 | PKR 80.65/tablet | 5% below median |
| Aroma | Azithromycin | 500 mg | Tablet | 10's | 099912 | PKR 901.39 | PKR 90.14/tablet | 6% above median |
| Atromont | Atorvastatin | 20 mg | Tablet | 10's | 119051 | PKR 279.22 | PKR 27.92/tablet | 42% below median |
| Atromont | Atorvastatin | 10 mg | Tablet | 10's | 119057 | PKR 164.99 | PKR 16.50/tablet | 42% below median |
| C-Oxylor | Chloroquine | 250 mg | Tablet | 500's | 106183 | PKR 489.90 | PKR 0.98/tablet | 37% below median |
| Cafaday | Ceftriaxone | 250 mg | Injection | Vial | 092551 | PKR 198.77 | PKR 198.77/vial/unit | Near median |
| Cafaday | Ceftriaxone | 500 mg | Injection | Vial | 092552 | PKR 334.58 | PKR 334.58/vial/unit | Near median |
| Cafaday | Ceftriaxone | 1 g | Injection | 1's | 092553 | PKR 631.76 | PKR 631.76/vial/unit | 5% above median |
| Ceviba 2.5gm InjectionRegistry verified | Ceftazidime as Pentahydrate/Avibactam as Sodium Salt | — | — | — | 135515Official source ↗ | No indexed price | — | — |
| Claromet | Clarithromycin | 250 mg | Tablet | 10's | 092559 | PKR 417.99 | PKR 41.80/tablet | 12% below median |
| Claromet | Clarithromycin | 500 mg | Tablet | 10's | 092563 | PKR 696.64 | PKR 69.66/tablet | 17% below median |
| Claromet Dry Susp | Clarithromycin | 250 mg/5 mL | Dry suspension | 60ml | 084096 | PKR 701.40 | PKR 11.69/mL | Near median |
| Claromet Dry Susp | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 084669 | PKR 423.88 | PKR 7.06/mL | Near median |
| Clio | Ciprofloxacin | 250 mg | Tablet | 10's | 084085 | PKR 252.25 | PKR 25.23/tablet | Near median |
| Clio | Ciprofloxacin | 500 mg | Tablet | 10's | 084086 | PKR 417.17 | PKR 41.72/tablet | Near median |
| Clio Susp | Ciprofloxacin | 125 mg/5 mL | Suspension | 60ml | 103387 | PKR 149.09 | PKR 2.48/mL | 30% below median |
| Clio Susp | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 103388 | PKR 265.04 | PKR 4.42/mL | 15% below median |
| Consio | Quetiapine | 25 mg | Tablet | 20's | 121457 | PKR 253.83 | PKR 12.69/tablet | 40% below median |
| Consio | Quetiapine | 100 mg | Tablet | 10's | 121458 | PKR 380.75 | PKR 38.08/tablet | 49% below median |
| Defos | Fosfomycin | 3 g | Sachet | 1's | 084052 | PKR 205.56 | PKR 205.56/sachet | No comparator |
| Demacro | Azithromycin | 250 mg | Capsule | 10's | 084088 | PKR 494.79 | PKR 49.48/capsule | Near median |
| Demacro Dry Susp | Azithromycin | 200 mg/5 mL | Dry suspension | 15ml | 084091 | PKR 313.63 | PKR 20.91/mL | Near median |
| Demal | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 30ml | 084095 | PKR 164.39 | PKR 5.48/mL | Near median |
| Demal | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 60ml | 084095 | PKR 328.78 | PKR 5.48/mL | Near median |
| Demal 40 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 095809 | PKR 431.92 | PKR 53.99/tablet | 16% below median |
| Demal 40 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 10's | 095809 | PKR 539.91 | PKR 53.99/tablet | 16% below median |
| Demal 80 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 095808 | PKR 431.04 | PKR 71.84/tablet | 34% below median |
| Demal 80 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 8's | 095808 | PKR 574.74 | PKR 71.84/tablet | 34% below median |
| Denzibet | Itraconazole | 100 mg | Capsule | 4's | 084894 | PKR 588.87 | PKR 147.22/capsule | Near median |
| Devicon 6g Sachet Polyethylene Glycol 13.125g + Sod.Chloride 0.3507g + Sod.Bicarbonate 0.1785 + Pot.Chloride 0.0466 gSource observed | — | 6 g | Sachet | 10's | 084055Official source ↗ | No indexed price | — | — |
| Doin | Ondansetron | 8 mg | Tablet | 10's | 094682 | PKR 1,091.49 | PKR 109.15/tablet | 35% below median |
| Doin | Ondansetron | 4 mg/5 mL | Syrup | 50ml | 127332 | PKR 634.59 | PKR 12.69/mL | 29% below median |
| Eficef | Cefixime | 400 mg | Capsule | 5's | 092558 | PKR 564.18 | PKR 112.84/capsule | Near median |
| Eficef Dry Powder Susp | Cefixime | 100 mg/5 mL | Suspension | 30ml | 092556 | PKR 314.84 | PKR 10.49/mL | Near median |
| Eficef Dry Powder Susp | Cefixime | 200 mg/5 mL | Suspension | 30ml | 092557 | PKR 385.29 | PKR 12.84/mL | Near median |
| Elilip 50/ Vidagliptin + | Vildagliptin + Metformin | 50 mg + 850 mg | Tablet | 14's | 095815 | PKR 960.77 | PKR 68.63/tablet | 31% below median |
| Elilip 50/ Vidagliptin + | Vildagliptin + Metformin | 50 mg + 500 mg | Tablet | 14's | 095816 | PKR 944.27 | PKR 67.45/tablet | No comparator |
| Evo | Levofloxacin | 250 mg | Tablet | 10's | 084034 | PKR 447.33 | PKR 44.73/tablet | 7% below median |
| Evo | Levofloxacin | 500 mg | Tablet | 10's | 084035 | PKR 744.37 | PKR 74.44/tablet | 6% below median |
| Feosol 100 | Iron + Folic acid | 100 mg + 0.35 mg | Chewable tablet | 30's | 100718 | PKR 390.94 | PKR 13.03/tablet | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.